Literature DB >> 1493922

Characterization of platelet-activating factor synthesized by normal and granulocyte-macrophage colony-stimulating factor-primed human eosinophils.

M Triggiani1, R P Schleimer, K Tomioka, W C Hubbard, F H Chilton.   

Abstract

Platelet-activating factor (PAF; 1-alkyl-2-acetyl-sn-glycero-3- phosphocholine) is a mediator involved in the pathogenesis of inflammatory diseases associated with tissue eosinophil infiltration. Previous studies utilizing bioassay or assaying enzymes associated with PAF biosynthesis have suggested that human eosinophils produce PAF. The present study has extended these initial studies by identifying and quantifying the different PAF molecular species and analogues synthesized by human eosinophils in response to A23187 and f-Met-Leu-Phe (FMLP). Gas chromatography-mass spectrometric analysis indicated that A23187-stimulated eosinophils produce at least three molecular species of PAF. The predominant species is 1-hexadecyl-2-acetyl-GPC (16:0) followed by 1-octadecyl-2-acetyl-GPC (18:0) and 1-octadecyl-2-acetyl-GPC (18:1). Eosinophils stimulated with FMLP produce approximately 100-fold smaller quantities of PAF relative to those produced in response to A23187 and only the 16:0 molecular species could be measured. A small percentage (comprising between 2 and 5%) of the 2-acetylated phospholipids produced by eosinophils was the 1-acyl analogue of PAF. Long-term (72 hr) incubation with granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in a three- to fourfold increase in PAF synthesis from eosinophils stimulated with FMLP, without changes in the profile of PAF molecular species or in the percentage of the 1-acyl analogue of PAF. These data indicate that human eosinophils can produce various molecular species of PAF and that this process can be quantitatively enhanced by GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493922      PMCID: PMC1421661     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine.

Authors:  E Benfenati; D Macconi; M Noris; G Icardi; L Bettazzoli; G De Bellis; M Gavinelli; S Rotondo; G Remuzzi
Journal:  J Lipid Res       Date:  1989-12       Impact factor: 5.922

2.  Biological effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in the human neutrophil.

Authors:  M Triggiani; D W Goldman; F H Chilton
Journal:  Biochim Biophys Acta       Date:  1991-06-19

3.  Degree of platelet activating factor-induced neutrophil migration is dependent upon the molecular species.

Authors:  E J Carolan; T B Casale
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

4.  The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function.

Authors:  R Hällgren; L Bjermer; R Lundgren; P Venge
Journal:  Am Rev Respir Dis       Date:  1989-02

5.  Species-specific variations in the molecular heterogeneity of the platelet-activating factor.

Authors:  C S Ramesha; W C Pickett
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

6.  Increased biosynthesis of platelet-activating factor in activated human eosinophils.

Authors:  T Lee; D J Lenihan; B Malone; L L Roddy; S I Wasserman
Journal:  J Biol Chem       Date:  1984-05-10       Impact factor: 5.157

7.  1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes.

Authors:  F H Chilton; J M Ellis; S C Olson; R L Wykle
Journal:  J Biol Chem       Date:  1984-10-10       Impact factor: 5.157

8.  Phospholipid analysis of human eosinophils: high levels of alkylacylglycerophosphocholine (PAF precursor).

Authors:  A Ojima-Uchiyama; Y Masuzawa; T Sugiura; K Waku; H Saito; Y Yui; H Tomioka
Journal:  Lipids       Date:  1988-08       Impact factor: 1.880

9.  Molecular heterogeneity of platelet-activating factor produced by stimulated human polymorphonuclear leukocytes.

Authors:  R N Pinckard; E M Jackson; C Hoppens; S T Weintraub; J C Ludwig; L M McManus; G E Mott
Journal:  Biochem Biophys Res Commun       Date:  1984-07-18       Impact factor: 3.575

10.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

View more
  2 in total

1.  Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor.

Authors:  R J Raggers; I Vogels; G van Meer
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

Review 2.  Regulation and metabolism of arachidonic acid.

Authors:  M C Seeds; D A Bass
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.